caa a22 4500 397592256 CHVBK 20180308164942.0 cr unu---uuuuu 161202e199603 xx s 000 0 eng 10.1093/jac/37.3.583 doi (NATIONALLICENCE)oxford-10.1093/jac/37.3.583 Multiple dose netivudine, a potent anti-varicella zoster virus agent, in healthy elderly volunteers and patients with shingles [Elektronische Daten] [R. W. Peck, P. Crome, M. J. Wood, M. W. McKendrick, B. Bannister, B. K. Mandal, R. J. Crooks] Netivudine is a nucleoside analogue with potent anti-varicella zoster virus activity. We now report two open studies of the pharmacokinetics and tolerability of netivudine in doses of 50, 100 and 200 mg twice daily. In one study, healthy volunteers received an initial, single dose followed, a week later, by repeat dosing for 9½ days; in the other, patients with shingles were treated for 8 days and data were also recorded for rash resolution and pain duration and intensity. Netivudine was well tolerated in both studies. Plasma concentrations were similar in patients and healthy volunteers and increased in proportion to dose. Steady state concentrations were 15-25% lower than expected from single dose data, probably because of slightly decreased netivudine absorption after food. Elimination half-life was 14-20 h. Plasma concentrations of 5-propynyluracil (5-PU), the main metabolite of netivudine, did not increase in proportion to the netivudine dose and tended to be higher in patients than volunteers. 5-PU concentrations remained elevated for up to 72 h after the last netivudine dose, suggesting continued but slow release from unabsorbed netivudine in the gut lumen. New lesion formation ceased and vesicles crusted most quickly in the 200 mg group; zoster-associated pain intensity, was reduced in a dose-related manner. © 1996 The British Society for Antimicrobial Chemotherapy Original articles nationallicence Peck R. W. Wellcome Research Laboratories Beckenham, Kent, BR3 3BS, UK. aut Crome P. Keele University School of Postgraduate Medicine, North Staffordshire Hospital Stok-on-Trent, ST4 7QB, UK. aut Wood M. J. Birmingham Heartlands Hospital Birmingham, B9 5ST, UK. aut McKendrick M. W. Royal Hallamshire Hospital Sheffield, S10 2JT, UK. aut Bannister B. Coppetts Wood Hospital London, N10 1JN, UK. aut Mandal B. K. North Manchester General Hospital Manchester, M8 5RB, UK. aut Crooks R. J. Wellcome Research Laboratories Beckenham, Kent, BR3 3BS, UK. aut Journal of Antimicrobial Chemotherapy Oxford University Press 37/3(1996-03), 583-597 0305-7453 37:3<583 1996 37 jac https://doi.org/10.1093/jac/37.3.583 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/37.3.583 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Peck R. W. Wellcome Research Laboratories Beckenham, Kent, BR3 3BS, UK aut NATIONALLICENCE 700 1- Crome P. Keele University School of Postgraduate Medicine, North Staffordshire Hospital Stok-on-Trent, ST4 7QB, UK aut NATIONALLICENCE 700 1- Wood M. J. Birmingham Heartlands Hospital Birmingham, B9 5ST, UK aut NATIONALLICENCE 700 1- McKendrick M. W. Royal Hallamshire Hospital Sheffield, S10 2JT, UK aut NATIONALLICENCE 700 1- Bannister B. Coppetts Wood Hospital London, N10 1JN, UK aut NATIONALLICENCE 700 1- Mandal B. K. North Manchester General Hospital Manchester, M8 5RB, UK aut NATIONALLICENCE 700 1- Crooks R. J. Wellcome Research Laboratories Beckenham, Kent, BR3 3BS, UK aut NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 37/3(1996-03), 583-597 0305-7453 37:3<583 1996 37 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford